A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
ConditionMyeloproliferative Neoplasms
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorIncyte Corporation
About this trial
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
Eligibility criteria
Qualifiers
Age 18 years or older at the time of signing the ICF
ECOG performance status of 0 to 1 for the dose escalation (Part 1a) and 0 to 2 for the dose expansion (Part 1b)
Documented CALR exon-9 mutation
DIPSS+ intermediate-2/high-risk MF with prior JAKi, <20% blasts, and measurable spleen
Disqualifiers
Major bleeding or thrombosis (e.g., stroke, DVT, PE) within the past 3 months
Active or high-risk HBV, HCV, or HIV infection, or other chronic active infections requiring systemic treatment
Active invasive cancer within the past 2 years, except certain early-stage or low-risk cancers (e.g., resected skin, cervical, thyroid, or prostate cancer)
Pregnant or unwilling to avoid pregnancy or fathering a child during the study and for a defined period after the last dose.
Trial design
Treatments tested in this trial
- INCA035784
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov